| Literature DB >> 26501257 |
Ting Min1, Jie Sun2, Yang Yi3,4, Hong-Xun Wang5,6, Fei Hang7, You-Wei Ai8, Li-Mei Wang9,10.
Abstract
A high performance size exclusion-fluorescence detection (HPSEC-FD) method combined with fluorescein isothiocyanate (FITC) prelabeling was established for the microanalysis of polysaccharide-protein complexes from longan pulp (LPP). FITC-labeled LPP (LPPF) was fractionated by gel filtration chromatography. The weight-average molecular weight and FITC substitution degree of LPPF were 39.01 kDa and 0.20%, respectively. The HPSEC-FD calibration curves linear over the range of 1-200 µg/mL in mouse plasma, spleen and lung samples with correlation coefficients greater than 0.995. The inter-day and intra-day precisions of the method were not more than 6.9%, and the relative recovery ranged from 93.7% to 106.4%. The concentration-time curve of LPPF in plasma following intravenous (i.v.) administration at 40 mg/kg body weight well fitted to a two-compartment model. LPPF rapidly eliminated from plasma according to the short half-lives (t1/2α=2.23 min, t1/2β=39.11 min) and mean retention times (MRT0-t=1.15 h, MRT0-∞=1.39 h). After administration over 5 to 360 min, the concentration of LPPF in spleen homogenate decreased from 7.41 to 3.68 µg/mL; the concentration in lung homogenate decreased from 9.08 to 3.40 µg/mL. On the other hand, the increasing concentration of LPPF fraction with low molecular weight in heart homogenate was observed.Entities:
Keywords: HPSEC-FD; distribution; longan pulp; pharmacokinetics; polysaccharide-protein complex
Mesh:
Substances:
Year: 2015 PMID: 26501257 PMCID: PMC4632757 DOI: 10.3390/ijms161024403
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Gel filtration chromatograms of crude longan polysaccharide-protein complexes treated with (Right) or without (Left) Fluorescein isothiocyanate (FITC).
Figure 2High performance size exclusion chromatograms of longan polysaccharide-protein complexes (LPP) (Left) and Fluorescein isothiocyanate-labeled LPP (LPPF) (Right) obtained by refractive index detection.
Figure 3Ultraviolet-visible (Left) and fluorescence spectra (Right) of LPP and LPPF. The excitation wavelength for fluorescence scanning was 495 nm.
Figure 4High performance size exclusion chromatograms of LPPF obtained by FD. (A) The chromatogram of 50 µg/mL LPPF prepared by phosphate buffer (pH 7.4); (B–G) The chromatograms of biological samples mixed with or without 50 µg/mL LPPF; (H) The chromatograms of heart samples from mice at predefined times (5, 10, 20 and 180 min) after a single intravenous (i.v.) administration of LPPF (40 mg/kg body weight).
Calibration curves for Fluorescein isothiocyanate-labeled longan polysaccharide-protein complexes (LPPF) in mouse plasma and tissue homogenate supernatants.
| Biological Samples | Standard Curves | Correlation Coefficients | Linear Ranges * (µg/mL) |
|---|---|---|---|
| Blank | 0.998 | 1–200 µg/mL | |
| Plasma | 0.996 | 1–200 µg/mL | |
| Spleen | 0.996 | 1–200 µg/mL | |
| Lung | 0.995 | 1–200 µg/mL |
* Data were obtained at six concentrations, and each repeated in triplicate.
Precision and accuracy for quantitative determination of LPPF by high performance size exclusion-fluorescence detection (HPSEC-FD) method.
| Biological Samples | Added Concentration (µg/mL) | Relative Recovery (%) | Precision ( | |
|---|---|---|---|---|
| Intra-Day | Inter-Day | |||
| Blank | 2 | 99.4 ± 4.3 | 3.4 | 4.0 |
| 40 | 101.7 ± 3.0 | 2.4 | 2.9 | |
| 80 | 101.4 ± 2.3 | 3.1 | 4.2 | |
| Plasma | 2 | 98.2 ± 5.1 | 4.5 | 4.5 |
| 40 | 102.3 ± 4.1 | 3.2 | 2.9 | |
| 80 | 103.4 ± 5.2 | 5.1 | 2.6 | |
| Spleen | 2 | 106.4 ± 3.9 | 3.6 | 3.5 |
| 40 | 96.7 ± 5.7 | 4.4 | 5.0 | |
| 80 | 105.4 ± 3.3 | 5.7 | 3.5 | |
| Lung | 2 | 93.7 ± 2.9 | 3.0 | 4.2 |
| 40 | 104.2 ± 3.1 | 4.4 | 3.8 | |
| 80 | 96.5 ± 3.4 | 2.5 | 6.9 | |
Figure 5LPPF concentration vs. time profile following intravenous (i.v.) administration at 40 mg/kg body weight. Data are represented as mean ± standard derivation (n = 5).
Pharmacokinetics parameters of LPPF after a single intravenous (i.v.) administration at 40 mg/kg (mean ± SD, n = 5).
| Parameters * | Values |
|---|---|
| Half-life of distribution phase | 2.23 ± 0.35 |
| Half-life of elimination phase | 39.11 ± 2.73 |
| Apparent volume of distribution of the central compartment | 0.09 ± 0.01 |
| Apparent volume of distribution of the peripheral compartment | 0.26 ± 0.03 |
| Clearance of the central compartment | 0.53 ± 0.03 |
| Clearance of the peripheral compartment | 0.60 ± 0.05 |
| Area under concentration–time curve | 56.80 ± 3.44 |
| Area under concentration–time curve | 58.85 ± 3.51 |
| Mean retention time | 1.15 ± 0.04 |
| Mean retention time | 1.39 ± 0.08 |
* The parameters including t1/2α, t1/2β, V1, V2, CL1 and CL2 were calculated by a two-compartmental moment analysis, and the other parameters were calculated by non-compartmental moment analysis.